Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Mirabegron 50mg + Solifenacine Succinate I.P. 5mg
Therapeutic Category
Urology
Dosage Form
Tablet
Packaging Type
Alu-Alu
Packaging
10x10
Price
₹599/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Miratyle S 50/5 Tablet is a combination of Mirabegron (50mg) and Solifenacin Succinate I.P. (5mg), formulated to provide comprehensive management of overactive bladder (OAB) symptoms. Mirabegron, a beta-3 adrenergic agonist, enhances bladder storage capacity by relaxing the detrusor muscle during the storage phase. Solifenacin Succinate, a muscarinic receptor antagonist, reduces involuntary bladder contractions and urgency. Together, these components synergistically alleviate urinary frequency, urgency, and urge incontinence, offering a dual mechanism of action for better symptom control and improved patient compliance.
This dual-action therapy is ideal for patients who experience insufficient symptom relief with monotherapy or who need a broader therapeutic approach to manage OAB. The tablet is designed for once-daily administration, providing convenience and sustained relief throughout the day.
Common side effects may include dry mouth, constipation, increased blood pressure, headache, and dizziness.
For the treatment of overactive bladder (OAB) symptoms, including urinary urgency, increased frequency, and urge incontinence.
Use only under medical supervision. Avoid in patients with severe liver or kidney impairment or uncontrolled hypertension.
Store in a cool, dry place below 30°C, away from light and moisture.
Composition : Mirabegron (25mg)
Composition : Mirabegron (50mg)
Composition : Alfuzosin (10mg) Tablet
Composition : Alfuzosin (10mg) + Dutasteride (0.5mg) Tablet
Composition : Disodium Hydrogen Citrate (1.40gm) Syrup
Composition : Tamsulosin (0.4mg)
Composition : Tamsulosin (0.4mg) + Tadalafil (5mg)
Composition : Ursodeoxycholic Acid (450mg) SR
Composition : Cranberry Extract 200mg + D-Mannose 300mg + Potassium Magnesium Citrate 978mg
Composition : Cranberry Extract(200.0 Mg/15ml)+Potassium Magnesium Citrate(978.0 Mg/15ml)+D Mannose(300.0 Mg/15ml)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Mirabegron + Solifenacin combination is a advanced urology therapy used for the management of overactive bladder (OAB) with symptoms like urinary urgency, frequency, nocturia, and urge incontinence. Mirabegron (50 mg) relaxes the bladder muscle by beta-3 agonist action, improving bladder storage capacity. Solifenacin (5 mg) is an antimuscarinic that reduces involuntary bladder contractions. This dual mechanism provides better symptom control than monotherapy, making it a premium and highly effective product in the urology and geriatric care segment.
Medical distributors and wholesalers can benefit from strong and growing demand from urologists, gynecologists, and physicians. Overactive bladder is a chronic and underdiagnosed condition, and combination therapy is increasingly preferred, ensuring repeat prescriptions, long-term usage, and stable market growth.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in urology, gynecology, and chronic care segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high specialist demand, increasing geriatric population, and strong chronic therapy adherence, making it a high-value, prescription-driven, and fast-growing pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in urology and chronic care formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the urology and geriatric healthcare segment.